PLEVA, Leos, Pavel KUKLA, Jana ZAPLETALOVA and Ota HLINOMAZ. Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study. Catheterization and Cardiovascular Interventions. Hoboken: Wiley-Blackwell, 2018, vol. 92, No 6, p. "E416"-"E424", 9 pp. ISSN 1522-1946. Available from: https://dx.doi.org/10.1002/ccd.27688.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study
Authors PLEVA, Leos (203 Czech Republic, guarantor), Pavel KUKLA (203 Czech Republic), Jana ZAPLETALOVA (203 Czech Republic) and Ota HLINOMAZ (203 Czech Republic, belonging to the institution).
Edition Catheterization and Cardiovascular Interventions, Hoboken, Wiley-Blackwell, 2018, 1522-1946.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.551
RIV identification code RIV/00216224:14110/18:00105325
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/ccd.27688
UT WoS 000451188300007
Keywords in English everolimus-eluting stent; in-stent restenosis; paclitaxel-eluting balloon
Tags 14110115, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 10/2/2019 15:37.
Abstract
Background The efficacy of paclitaxel-eluting balloon catheters (PEB) and drug-eluting stents for treatment of bare-metal stent restenosis (BMS-ISR) have been demonstrated in several studies with follow-up times of 9 to 12 months; however, the long-term outcomes of ISR treatment are less defined. Objectives Methods We aimed to compare the long-term efficacy of PEB and everolimus-eluting stents (EES) for the treatment of BMS-ISR. We analyzed 3-year clinical follow-up data from patients included in the TIS randomized clinical study. A total of 136 patients with BMS-ISR were allocated to receive treatment with either PEB or EES (68 patients with 74 ISR lesions per group). Results Conclusions The PEB and EES groups did not significantly differ in major adverse cardiac events-free survival (MACE; P = .211; including individual events: CV death: P = .622; myocardial infarction: P = .650 or target vessel revascularization: P = .286) at 3-year clinical follow-up. No event-free survival differences were found between the groups regarding overall mortality (P = .818), definite stent thrombosis (P = .165) or the second MACE (P = .270). At the 3-year follow-up, no significant differences in clinical outcomes were found between iopromide-coated PEB and EES for the treatment of BMS-ISR. (; ; NCT01735825).
PrintDisplayed: 23/7/2024 22:14